ScandiDos AB (SDOS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, ScandiDos AB (SDOS) has a cash flow conversion efficiency ratio of 0.015x as of January 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr633.00K ≈ $68.12K USD) by net assets (Skr41.83 Million ≈ $4.50 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how many days can ScandiDos AB fund operations to measure how many days the company can operate on defensive assets alone.
ScandiDos AB - Cash Flow Conversion Efficiency Trend (2013–2025)
This chart illustrates how ScandiDos AB's cash flow conversion efficiency has evolved over time, based on yearly financial data.
ScandiDos AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ScandiDos AB ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
YGL Convergence Bhd
KLSE:0086
|
0.001x |
|
2cureX AB
ST:2CUREX
|
3.288x |
|
Mangoceuticals, Inc. Common Stock
NASDAQ:MGRX
|
-0.079x |
|
Nexgel Inc
NASDAQ:NXGL
|
-0.112x |
|
GRAND PEAK CAPITAL
F:6GP1
|
-0.012x |
|
Willow Biosciences Inc
TO:WLLW
|
0.055x |
|
THOR MNG CUFS/1LS- 00001
F:T5MB
|
N/A |
|
Ronin Resources Ltd
AU:RON
|
-0.059x |
Annual Cash Flow Conversion Efficiency for ScandiDos AB (2013–2025)
The table below shows the annual cash flow conversion efficiency of ScandiDos AB from 2013 to 2025. For the full company profile with market capitalisation and key ratios, see market value of ScandiDos AB.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-04-30 | Skr44.98 Million ≈ $4.84 Million |
Skr230.00K ≈ $24.75K |
0.005x | -84.75% |
| 2024-04-30 | Skr44.29 Million ≈ $4.77 Million |
Skr1.49 Million ≈ $159.81K |
0.034x | +111.74% |
| 2023-04-30 | Skr41.65 Million ≈ $4.48 Million |
Skr-11.90 Million ≈ $-1.28 Million |
-0.286x | -544.53% |
| 2022-04-30 | Skr37.20 Million ≈ $4.00 Million |
Skr2.39 Million ≈ $257.31K |
0.064x | -66.38% |
| 2021-04-30 | Skr45.18 Million ≈ $4.86 Million |
Skr8.64 Million ≈ $929.59K |
0.191x | +256.15% |
| 2020-04-30 | Skr46.26 Million ≈ $4.98 Million |
Skr-5.66 Million ≈ $-609.54K |
-0.122x | +73.68% |
| 2019-04-30 | Skr28.62 Million ≈ $3.08 Million |
Skr-13.31 Million ≈ $-1.43 Million |
-0.465x | -136.41% |
| 2018-04-30 | Skr46.58 Million ≈ $5.01 Million |
Skr-9.17 Million ≈ $-986.52K |
-0.197x | +34.23% |
| 2017-04-30 | Skr44.00 Million ≈ $4.74 Million |
Skr-13.17 Million ≈ $-1.42 Million |
-0.299x | +48.40% |
| 2016-04-30 | Skr32.00 Million ≈ $3.44 Million |
Skr-18.56 Million ≈ $-2.00 Million |
-0.580x | -36.36% |
| 2015-04-30 | Skr25.34 Million ≈ $2.73 Million |
Skr-10.78 Million ≈ $-1.16 Million |
-0.425x | -288.06% |
| 2014-04-30 | Skr40.48 Million ≈ $4.36 Million |
Skr-4.44 Million ≈ $-477.49K |
-0.110x | -148.42% |
| 2013-04-30 | Skr10.21 Million ≈ $1.10 Million |
Skr2.31 Million ≈ $248.70K |
0.226x | -- |
About ScandiDos AB
ScandiDos AB (publ), together with its subsidiaries, provides measurement phantoms and software solutions for the quality assurance and validation of dynamic and modulated treatments adopted in clinics in the United States, Europe, Asia, and internationally. The company offers Delta4 products comprising Delta4 Phantom+, Delta4Phantom+MR, Delta4 HexaMotion, Delta4Insight, Delta4DVH Anatomy, Delta4… Read more